Advances of immune checkpoint blockades in the treatment of digestive cancers

Immune checkpoint blockade is a hot spot in treatment of cancers recently, and their effi-cacy in digestive cancer cannot been ignored. Nivolumab is superior to sorafenib in the terms of prolonging survival period for the patients with advanced live cancer. The effective rate of Pembrolizumab for advanced PD-L1 positive expression esophageal cancer can reach 30%. Nevertheless, Ipilumumab shows no significant efficacy in advanced pancreatic carcinoma. More researches are on the way, such as Avelumab in advanced gastric cancer, and Pembrolizumab in advanced esophageal squamous carcinoma. Key words: Digestive system neoplasms; Therapy; Immune checkpoint blockades